
    
      Monocentric, open-label, single-arm phase II study evaluating safety and efficacy of
      neoadjuvant radiotherapy in early breast cancer patients. Patients eligible are women aged 50
      or more years old, affected by histologically proven invasive breast cancer, with positive
      hormonal receptors, grading 1 or 2, HER-2 negative, without lymphovascular invasion, and
      tumour size up to 2 cm (measured on mammography, ultrasound or magnetic resonance), negative
      clinical nodal status, eligible for BCS.
    
  